Bio Farma Boss Dismantles 10 Frauds That Occurred At Indofarma

President Director of Bio Farma Shadiq Akasya. (Photo: Doc. ANTARA)

JAKARTA - Bio Farma President Director Shadiq Akasya uncovered 10 indications of fraud in his subsidiary, PT Indofarma Tbk which caused state losses of Rp436.87 billion.

First, said Shadiq, there were findings of indications of losses in Indofarma's subsidiary, PT Indofarma Global Medika (IGM) worth IDR 157.33 billion for transactions of the Fast Moving Consumer Goods (FMCG) business unit.

"Then, an indication of a loss in the emergency room for the loss of deposits is approximately Rp. 35.07 billion, an indication of an emergency loss for a deposit loss of Rp. 38 billion," he said in a meeting with Commission VI of the DPR, at the DPR Building, Jakarta, Wednesday, June 19.

Ketiga, sambung Shadiq, adanya indikasi kerugian IGM atas pengadaan deposito bersama bunga senilai Rp38,06 miliar pada Bank Oke.

Then, continued Shadiq, indications of IGM losses worth Rp. 18 billion were found for the return of the down payment from MMU which did not go to the emergency room account.

"Fifth, expenditure and charge costs without being based on transactions with indications of IGM losses of IDR 24.35 billion," he explained.

Sixth, continued Shadiq, the collaboration between the TeleCTG Alkes Distribution and PT ZTI without Memadai's plan indicated a loss to IGM of IDR 4.50 billion over payments that exceeded the value of the invoice and could potentially harm IGM worth IDR 10.43 billion over TeleCTG's unsold stock.

Then, continued Shadiq, loans through fintech are not for the benefit of companies indicating a loss to IGM worth IDR 1.26 billion.

Eighth, the business activities of masks without adequate planning indicated fraud, with an indication of a loss of IDR 2.67 billion for the decrease in the value of mask supplies and a potential loss of IDR 60.24 billion for PT Promedik's bad debt and IDR 13.11 billion for the remaining supply of masks.

Ninth, the purchase and sale of the Panbio Rapid Test of PT IGM without adequate planning indicated fraud and a potential loss of Rp56.70 billion for PT Promedik's bad debt.

"Tenth, PT Indofarma carries out the purchase and sale of PCR Kit COVID-19 in 2020/2021 without adequate planning with indications of fraud and a potential loss of IDR 5.98 billion for PT Promedik traffic jams and IDR 9.17 billion for the unsold PCR Kit COVID-19," said Shadiq.

Referring to the findings of the Supreme Audit Agency (BPK), the potential for Indofarma fraud and its subsidiary, Indofarma Global Medika, reached IDR 436.87 billion.